582 related articles for article (PubMed ID: 33572274)
1. Understanding Viral Infection Mechanisms and Patient Symptoms for the Development of COVID-19 Therapeutics.
Choi HM; Moon SY; Yang HI; Kim KS
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33572274
[TBL] [Abstract][Full Text] [Related]
2. Contributions of human ACE2 and TMPRSS2 in determining host-pathogen interaction of COVID-19.
Senapati S; Banerjee P; Bhagavatula S; Kushwaha PP; Kumar S
J Genet; 2021; 100(1):. PubMed ID: 33707363
[TBL] [Abstract][Full Text] [Related]
3. The expression of hACE2 receptor protein and its involvement in SARS-CoV-2 entry, pathogenesis, and its application as potential therapeutic target.
Al-Zaidan L; Mestiri S; Raza A; Merhi M; Inchakalody VP; Fernandes Q; Taib N; Uddin S; Dermime S
Tumour Biol; 2021; 43(1):177-196. PubMed ID: 34420993
[TBL] [Abstract][Full Text] [Related]
4. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19.
Kuba K; Yamaguchi T; Penninger JM
Front Immunol; 2021; 12():732690. PubMed ID: 35003058
[TBL] [Abstract][Full Text] [Related]
6. Targeting the viral-entry facilitators of SARS-CoV-2 as a therapeutic strategy in COVID-19.
Muralidar S; Gopal G; Visaga Ambi S
J Med Virol; 2021 Sep; 93(9):5260-5276. PubMed ID: 33851732
[TBL] [Abstract][Full Text] [Related]
7. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
Li K; Meyerholz DK; Bartlett JA; McCray PB
mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
[TBL] [Abstract][Full Text] [Related]
8. Insights into SARS-CoV-2: Medicinal Chemistry Approaches to Combat Its Structural and Functional Biology.
Zhuo LS; Wang MS; Yang JF; Xu HC; Huang W; Shang LQ; Yang GF
Top Curr Chem (Cham); 2021 Apr; 379(3):23. PubMed ID: 33886017
[TBL] [Abstract][Full Text] [Related]
9. Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity.
Essalmani R; Jain J; Susan-Resiga D; Andréo U; Evagelidis A; Derbali RM; Huynh DN; Dallaire F; Laporte M; Delpal A; Sutto-Ortiz P; Coutard B; Mapa C; Wilcoxen K; Decroly E; Nq Pham T; Cohen ÉA; Seidah NG
J Virol; 2022 Apr; 96(8):e0012822. PubMed ID: 35343766
[TBL] [Abstract][Full Text] [Related]
10. A Review on SARS-CoV-2-Induced Neuroinflammation, Neurodevelopmental Complications, and Recent Updates on the Vaccine Development.
Karnik M; Beeraka NM; Uthaiah CA; Nataraj SM; Bettadapura ADS; Aliev G; Madhunapantula SV
Mol Neurobiol; 2021 Sep; 58(9):4535-4563. PubMed ID: 34089508
[TBL] [Abstract][Full Text] [Related]
11. Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2).
Xiang Y; Wang M; Chen H; Chen L
Biochem Pharmacol; 2021 Oct; 192():114724. PubMed ID: 34371003
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of ACE2-Spike Interaction by an ACE2 Binder Suppresses SARS-CoV-2 Entry.
Shin YH; Jeong K; Lee J; Lee HJ; Yim J; Kim J; Kim S; Park SB
Angew Chem Int Ed Engl; 2022 Mar; 61(11):e202115695. PubMed ID: 35043545
[TBL] [Abstract][Full Text] [Related]
13. Severe acute respiratory syndrome coronavirus 2 for physicians: Molecular characteristics and host immunity (Review).
Shang J; Du L; Han N; Lv D; Wang J; Yang H; Bai L; Tang H
Mol Med Rep; 2021 Apr; 23(4):. PubMed ID: 33576464
[TBL] [Abstract][Full Text] [Related]
14. Precision therapeutic targets for COVID-19.
Krumm ZA; Lloyd GM; Francis CP; Nasif LH; Mitchell DA; Golde TE; Giasson BI; Xia Y
Virol J; 2021 Mar; 18(1):66. PubMed ID: 33781287
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanisms and epidemiology of COVID-19 from an allergist's perspective.
Hosoki K; Chakraborty A; Sur S
J Allergy Clin Immunol; 2020 Aug; 146(2):285-299. PubMed ID: 32624257
[TBL] [Abstract][Full Text] [Related]
16. Expression of ACE2 and TMPRSS2 Proteins in the Upper and Lower Aerodigestive Tracts of Rats: Implications on COVID 19 Infections.
Sato T; Ueha R; Goto T; Yamauchi A; Kondo K; Yamasoba T
Laryngoscope; 2021 Mar; 131(3):E932-E939. PubMed ID: 32940922
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2, ACE2 expression, and systemic organ invasion.
Ashraf UM; Abokor AA; Edwards JM; Waigi EW; Royfman RS; Hasan SA; Smedlund KB; Hardy AMG; Chakravarti R; Koch LG
Physiol Genomics; 2021 Feb; 53(2):51-60. PubMed ID: 33275540
[TBL] [Abstract][Full Text] [Related]
18. Pathogenic Basis of Thromboinflammation and Endothelial Injury in COVID-19: Current Findings and Therapeutic Implications.
Higashikuni Y; Liu W; Obana T; Sata M
Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769508
[TBL] [Abstract][Full Text] [Related]
19. The Ineluctable Role of ACE-2 Receptors in SARS COV-2 Infection and Drug Repurposing as a Plausible SARS COV-2 Therapy: A Concise Treatise.
Joseph S; Nair B; Nath LR
Curr Mol Med; 2021; 21(10):888-913. PubMed ID: 33563197
[TBL] [Abstract][Full Text] [Related]
20. Targeting Host Cell Proteases to Prevent SARS-CoV-2 Invasion.
Kaur U; Chakrabarti SS; Ojha B; Pathak BK; Singh A; Saso L; Chakrabarti S
Curr Drug Targets; 2021; 22(2):192-201. PubMed ID: 32972339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
